Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Frequently asked questions
What sector does KLRS (KLRS) operate in?
KLRS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is KLRS (KLRS) current stock price?
As of the latest data, KLRS stock price is $2.70, with a previous close of $2.85. KLRS lost -$0.15 in the last trading session, representing a -5.26% loss.
What is KLRS (KLRS) current market capitalization?
KLRS market cap is approximately 64.27 million.
What is KLRS (KLRS) Earnings Per Share (EPS)?
The trailing EPS is -$1.90, and the forward EPS is -$1.66.
What is KLRS (KLRS) EBITDA?
KLRS EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -12.38 million.
Does KLRS (KLRS) pay dividends?
No. KLRS does not pay a dividend.
What is KLRS (KLRS) beta (volatility) score?
KLRS has a beta of 1.132, meaning its volatility is roughly in line with the market.
